Want to join the conversation?
In the near term, $VRTX expects cash flow from product revenues to increase due to sales of cystic fibrosis drug Orkambi in the U.S. after receipt of FDA approval in July. $VRTX does not expect significant product revenue from Orkambi in 2015 from ex-U.S. markets.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th